Trial Profile
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Favezelimab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Quavonlimab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms KeyImPaCT; KEYNOTE-495
- Sponsors Merck Sharp & Dohme Corp.
- 01 Jul 2023 Interim Results assessing the safety and efficacy of Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancerpublished in the Nature Medicine
- 04 May 2022 Planned End Date changed from 20 Oct 2025 to 28 Jun 2025.
- 04 May 2022 Planned primary completion date changed from 20 Oct 2025 to 28 Jun 2025.